CERUS CORP
About CERUS CORP
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety, and generates revenue from the same.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $233.8M
- Net income
- -$15.6M
- Total assets
- $221.9M
- Market cap
- $543.0M
- Operating margin
- -3.7%
- Net margin
- -6.7%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $233.8M
- Operating expenses
- $148.6M
- Operating income
- -$8.7M
- Income tax
- $354.0K
- Net income
- -$15.6M
- EPS (basic)
- $-0.08
- EPS (diluted)
- $-0.08
Balance sheet
- Total assets
- $221.9M
- Current assets
- $174.4M
- Total liabilities
- $156.9M
- Current liabilities
- $100.8M
- Shareholders’ equity
- $65.0M
Cash flow
- Operating cash flow
- $4.8M
- Investing cash flow
- -$6.2M
- Financing cash flow
- $231.0K
- Net cash flow
- -$761.0K
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $543.0M
- EPS (diluted)
- $-0.08
- Shares outstanding
- 212.1M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jan 31, 1997
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $15.6M in FY2025.
- Revenue grew 47% from FY2021 to FY2025.
- Trading 16% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review CERUS CORP.
Write a review
News about CERUS CORP
News & sentiment via Polygon.io
